August 16, 2022 (Investorideas.com Newswire) Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its “Buy” rating and $6/share price target on Magenta Therapeutics.
In an August 5, 2022 research note, Biotechnology Technology Equity Research LLC (BTIG LLC) Analyst Yun Zhong, Ph.D. advised that Magenta Therapeutics Inc. (MGTA:NASDAQ) recently announced updates on the status of its drug development pipeline during Q2/22 and suggested that all its programs are moving forward as scheduled.
BTIG stated it is reiterating its Buy rating for the company as it sees promising potential for Magenta’s pipeline in targeting hematopoietic stem cell transplant (HSCT) and gene therapy.
The analyst advised that Magenta Therapeutics is expected to report updated clinical data for its MGTA-117 and MGTA-145 in Q4/22, which will serve as key catalysts for the company.
BTIG noted that early in the Phase 1/2 MGTA-117 clinical study, four subjects in cohort 1 who were given the lowest dose of 0.02mg/kg did not experience any adverse effects and showed good target engagement and rapid clearance within 48 hours after dosing.
In an update from the company on August 4, 2022, Magenta indicated that it is seeing consistent observations from members in the higher dose cohort but did not list any additional details regarding the number of patients treated and evaluated or the specific dose escalation data.
The analyst advised that the firm’s management intends to provide a clinical update in Q4/22, which BTIG believes will give credence to discussions with the FDA to move the study forward into transplant-eligible patients.
In addition, Magenta is collaborating with bluebird bio Inc. (BLUE:NASDAQ) not rated by BTIG in a new Phase 2 study of MGTA-145 in patients with sickle cell disease (SCD). The firm estimates that initial data from the trial will be available sometime during Q4/22.
Magenta listed in its quarterly update that as of June 30, 2022, it held $139.4 million in cash and cash equivalents on its balance sheet, which it said is sufficient to fund the company into Q2/24.
The analyst remarked that Magenta has also entered into collaboration agreements with two other companies for the purpose of developing MGTA-117 as “a nongenotoxic conditioning regimen in gene therapy and genome editing treatment.”
BTIG mentioned that “it believes that the application in gene therapy should be a particularly promising opportunity for strong growth and that there should be considerable upside upon increased adoption of HSCT in indications where the procedure is not widely used despite being the only curative treatment option (i.e., autoimmune diseases and hemoglobinopathies other than SCD).”
The analyst noted that there are several upcoming catalysts that are all expected to take place in Q4/22. These include interim results from the Phase 1/2 study in patients with r/r AML or MDSEB not eligible for HSCT, discussions with the FDA related to the advancement of its CD45-antibody-drug conjugate program, clinical development plan, and schedule following the evaluation of clinical data from dose-ranging toxicology and GLP toxicology studies MGTA-145 for HSCT mobilization, and receipt of initial data from its Phase 2 trial.
BTIG stated that expects that the FDA will grant approval for MGTA-145 2026 for use in SCD patients and mentioned that there is potential upside for future approval by the FDA for the use of MGTA-145 in ?-thalassemia.
The added that it also expects that the FDA will authorize the use of MGTA-117 for AML, MDS, and SCD) patients in 2026.
The analyst commented that in Q2/22, Magenta expects to engage in discussions with the FDA to map out the next steps for its CD45-antibody-drug conjugate program. The CD45-ADC program could expand the firm’s pipeline as it applies in particular for use in autologous transplants for severe autoimmune diseases. The analyst listed that CD45-ADC offers strong prospects for use in the treatment of multiple sclerosis, scleroderma, leukemia, and non-Hodgkin lymphoma (NHL).
Magenta Therapeutics is a clinical-stage biotech firm focused development of medicines that are engineered to optimize the stem cell transplant process in order to improve treatment outcomes and increase patient eligibility in the transplant addressable population in the areas of genetic diseases hematologic cancer, and other additional indications.
Biotechnology Technology Equity Research advised that it has a Buy rating and a $6.00 price target for Magenta Therapeutics Inc. BTIG indicated that it arrived at that price by employing a combination of discounted earnings, cash flow, and clinical net present value (NPV) models. The research firm noted that its revenue projections include sales for both MGTA-145 and MGTA-117 for respective use in HSC mobilization and conditioning prior to HSCT.
Magenta Therapeutics shares trade on the Nasdaq Exchange under the symbol “MGTA” and last closed for trading at $1.77 on Friday, August 12, 2022. The company has approximately 58.8 million shares outstanding and a market cap of about $104.1 million.
1) Stephen Hytha wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with None. Please click here for more information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for BTIG Research, Magenta Therapeutics, August 5, 2022
Analyst Certification: I, Yun Zhong, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
Company-Specific Regulatory Disclosures: BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Magenta Therapeutics (MGTA).
Other Disclosures: Additional Information Available Upon Request.
General Disclosures: Research reports produced by BTIG LLC (“BTIG”) are published for and intended to be distributed solely to BTIG institutional and corporate clients. Recipients of BTIG reports will not be considered clients of BTIG solely because they may have received such BTIG report.
To the extent recipient accesses BTIG research, whether on a BTIG research website or through a third-party platform, BTIG is able to search, filter, download and review information on the readership of BTIG’s research, including the specific research consumed and the name, company name, email address and, in certain circumstances, the location of the individual who accessed the research (the “Readership Information”). Recipient consents to BTIG’s receipt of the Readership Information, including receipt of that information from a third party.
The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues. BTIG reports are based on public information and BTIG considers the same to be reliable, comprehensive information, but makes no representation or warranty that the reports are accurate or complete. BTIG opinions and information provided in this report are as of the date of the report and may change without notice. An issuer may be classified as “Under Review” or “Research Restricted”. In these cases, investors should consider any previous investment recommendation and/or rating to a subject company/issuer to no longer be current and should not be relied upon nor considered a solicitation. This research report is not an offer to buy or sell or solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal. This research report was not drafted specifically for any particular individual or entity and is not a personal recommendation to participate in any particular trading strategy or transaction.
Any recipient of this research report should obtain independent advice specific to their personal circumstances before undertaking any investment activity and must make their own independent evaluation of any securities or financial instruments. Facts, views or opinions presented in this report have not been reviewed by, and may not reflect information known to, employees or other professionals in the “BTIG Group” (BTIG Group includes, but is not limited to, BTIG and its parents, subsidiaries and/ or affiliates). BTIG Group employees, including Sales Representatives and Traders, may provide oral or written commentary or advice that may be inconsistent with the opinions and/or views expressed in this research report. BTIG Group employees and/or its affiliates not involved in the preparation of this research report may have investments in securities or derivatives of securities of companies mentioned in this report that are inconsistent with the views discussed in this report.
Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors within or beyond the companies’ control. Recipient of the research reports should be aware that investments in securities may pose significant risks due to the inherent uncertainty associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company.
Any investment in securities should be undertaken only upon consideration of issues relating to the recipient’s overall investment portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs. Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options or other rights in any securities transactions.
Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public disclosure relating to their financial condition or the securities that they issue.
BTIG is a U.S. broker-dealer and member of FINRA and SIPC.
This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
BiotechIndustryStocks.com – investing ideas in biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech Stocks Directory